Applications of DNA Transfection in CRISPR/Cas9 Genome Editing
DNA transfection plays a pivotal role in the delivery of CRISPR/Cas9 components for targeted genome editing. The ability to introduce plasmids encoding Cas9 nuclease and guide RNA (gRNA) sequences into cells enables precise modification of endogenous genes, making DNA transfection a cornerstone technique in functional genomics and therapeutic research.
Efficient delivery of CRISPR/Cas9 plasmids requires overcoming multiple cellular barriers including cellular uptake, endosomal escape, nuclear import, and expression stability. Plasmid size, often exceeding 9 kilobases due to the inclusion of Cas9 and regulatory elements, poses challenges for conventional transfection reagents, necessitating optimization of delivery methods such as electroporation or advanced liposomal formulations.
Transient transfection of CRISPR components is frequently preferred to limit off-target effects and reduce persistent nuclease activity. This approach allows temporal control over gene editing while minimizing cytotoxicity associated with prolonged expression. Stable integration methods are employed when long-term Cas9 expression is needed, such as in cell line engineering or animal model development.
Following delivery, successful genome editing is confirmed through PCR-based genotyping, sequencing, or functional assays assessing gene knockout or knock-in. The efficiency of editing depends on transfection success, gRNA design, and cellular DNA repair pathways, including non-homologous end joining (NHEJ) and homology-directed repair (HDR).
Recent advancements incorporate DNA transfection of CRISPR base editors and prime editors, expanding the toolkit for precise single-base substitutions without double-strand breaks. The design of vectors expressing multiple gRNAs enables multiplexed editing of several genomic loci simultaneously.
Overall, DNA transfection remains a critical enabling technology for CRISPR/Cas9-mediated genome engineering, facilitating advances in disease modeling, gene therapy development, and functional genomics.